Novacyt Full Of Eastern Promise, Following Strong H1 Sales
Executive Summary
Cervical cancer screening firm Novacyt is aiming to broaden its market penetration in Asia-Pacific by identifying strategic acquisitions. The Anglo-French firm posted strong sales growth of 40% for the first six months of 2017, with APAC representing the group's fastest growing region.
You may also be interested in...
Novacyt Lands New US Supply Deal, Maps Path To Profitability
Novacyt is continuing its quest to reach profitability in 2018. The French diagnostics group has entered into a partnership with US lab Genesis Diagnostics to develop and supply molecular assay panels for a range of indications. The five-year deal is worth a minimum of $3m, but Novacyt said it expects the agreement to deliver more significant returns.
Novacyt Confident Of Further APAC Growth
Clinical diagnostics firm Novacyt is confident of further growth in Asia-Pacific after sales in China exceeded the company's expectations.
Novacyt Enlists MDL Asia To Step Up APAC Liquid Cytology Sales
Cervical cancer screening specialist Novacyt is intensifying its international commercial focus by enlisting MDL Asia to take charge of product distribution across Asia-Pacific, excluding Greater China.